Developing new treatments to eliminate HIV from the body
Official title: Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal
Funded at University of California Los Angeles · NIH-11012355 · Data updated 2026-11-12
This study is exploring new ways to help people with HIV by waking up hidden HIV-infected cells so that they can be targeted and destroyed, which could lead to better treatments and possibly even a cure, reducing the need for lifelong medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $721,067 |
| NIH project number | 5R01AI172410-03 |
| Project ID | NIH-11012355 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy.
✕Less likely to help
Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
What this research studies
This research focuses on finding effective ways to eliminate HIV from the body by targeting and activating dormant HIV-infected cells. The approach, known as 'kick and kill', aims to awaken these cells so that they can be destroyed by the immune system or other therapies. The researchers will design and test new compounds that can enhance this process, potentially leading to a cure for HIV. Patients may benefit from advancements in treatment strategies that could reduce or eliminate the need for lifelong antiretroviral therapy.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, allowing patients to stop lifelong antiretroviral therapy.
How similar studies have gone: Previous research has shown promise in using similar 'kick and kill' strategies to target HIV reservoirs, indicating potential for success in this approach.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Zack, Jerome a. — University of California Los Angeles
- Study coordinator: Zack, Jerome a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.